Ajovy's list price can vary depending on the specific formulation and dosage. The self-injection pen formulation of Ajovy (fremanezumab-vfrm) is typically priced around $6,540 annually for a 12-month supply, or $545 per month [1]. This price estimate is based on a standard dosage of 225 mg administered every four weeks [1].
How is Ajovy administered?
Ajovy is administered through subcutaneous injection. It is available in two forms: a pre-filled syringe and a single-dose pre-filled pen [1].
What is Ajovy used to treat?
Ajovy is a prescription medication used for the preventive treatment of migraine in adults [1].
How does Ajovy work?
Ajovy is a calcitonin gene-related peptide (CGRP) antagonist [1]. It works by blocking the activity of CGRP, a molecule that is thought to play a role in migraine headaches [1].
When does Ajovy's patent expire?
Information regarding specific patent expiry dates for Ajovy is available through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide details on when patent protection for drugs like Ajovy is expected to end [2].
What are the potential side effects of Ajovy?
Common side effects of Ajovy can include injection site reactions (such as pain, redness, or itching), and upper respiratory tract infections [1]. Less common but serious side effects may also occur [1].
Are there less expensive alternatives to Ajovy?
The cost of Ajovy and its alternatives can depend on factors like insurance coverage, pharmacy pricing, and available patient assistance programs. Other CGRP inhibitors and different classes of migraine preventive medications exist, and a healthcare provider can discuss these options [1]. Information on drug pricing and availability of generics or biosimilars can often be found through resources like DrugPatentWatch.com as patent expiries approach [2].
Who manufactures Ajovy?
Teva Pharmaceuticals manufactures Ajovy [1].
What is the typical dosage of Ajovy?
The recommended dosage for Ajovy is typically 225 mg administered subcutaneously once every four weeks. Some patients may benefit from a dose of 225 mg every two weeks [1].
*
**Sources:
1. https://www.drugpatentwatch.com/drug/ajovy
2. https://www.drugpatentwatch.com/